Overview:

uniQure (Nasdaq: QURE) has been a public company since 2014.

We thank our investors for their support as we advance our gene therapy pipeline toward commercialization.
Contact us at any time.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders.

We are leveraging our modular and validated technology platform to rapidly advance a focused pipeline of gene therapies.

Stock Quote

Recent News

 

 

Upcoming Events:

June 19, 2019
uniQure Annual General Meeting
9:30 - 10:30 a.m. CET
2019 AGM Notice
2019 Proxy Statement and Agenda 
2019 Proxy Card
2018 Annual Report
2018 Auditors Report

Webcast Archive:

March 12, 2019
Cowen & Company 39th Annual Healthcare Conference
10:40 a.m. ET/ 15:40 CET
Click here to view webcast

February 8, 2019
uniQure Conference Call: AMT-061 Phase 2b data at EAHAD 
8:30 a.m. ET/ 14:30 CET
Click here to view webcast

November 19, 2018 
uniQure R&D Day 2018
08:30 a.m. ET / 14:30 CET
Click here to view webcast